Per todays PR, the next P trial (not stated if a 2b, 2/3, or 3) will be for moderate to severe psoriasis. I think it is fair to say that the company did not see enough improvment in patients witg mild psoriasis to move forward.
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
